Cosmos Health Inc. has announced the acquisition of buy-out rights and exclusive licensing for two patented anticancer drugs. These therapies target a range of cancers, including prostate, ovarian, and colorectal, and are poised to enter Clinical Phase I trials. The move significantly expands Cosmos Health's oncology portfolio.
Novel Anticancer Therapies
These anticancer therapies are protected by international patents and represent a significant advancement in oncology research. The first therapy is protected by WIPO patent WO 2017/001439, valid in key markets including the EU, USA, Canada, Japan, China, and Australia. The second therapy is covered by EU patent EP3484892, internationally filed under WO 2018/011414 A1, with a focus on major markets such as the USA, Canada, Japan, China, and Australia.
Cosmos Health will oversee the further development and commercialization of both drugs. According to Greg Siokas, CEO of Cosmos Health, this agreement marks a transformative moment for the company, broadening their portfolio and reaffirming their dedication to addressing pressing challenges in oncology. Siokas believes these compounds have the potential to significantly impact cancer treatment paradigms.
Independent Valuation and Market Opportunity
An independent valuation by a leading global audit and advisory firm estimates the fair value of the patents at approximately $24.61 million USD, with a range of $22.80 million to $26.55 million. This valuation is based on the current pre-clinical phase, with potential for significant increases upon advancement toward commercialization.
The global oncology market continues to grow, driven by advancements in targeted treatments, increased adoption of immunotherapy, and rising investments in cancer research. Grand View Research projects the global ovarian cancer drug market to reach $6.3 billion by 2030, with a CAGR of 14.6%. The prostate cancer therapeutics market is expected to reach $21.48 billion (CAGR of 8.4%), and the colorectal cancer therapeutics market is forecasted to reach $16.7 billion (CAGR of 4.7%) by the same year.
About the Drugs
One drug, esters of steroidal lactam and bis(2-chloroethyl) aminophenoxy propanoic acid derivatives, exhibits higher antitumor activity and lower acute toxicity compared to conventional alkylating agents. Preclinical studies suggest that LSEs induce moderate to strong dual inhibition of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR signal transduction cellular pathways, as well as inhibit PARP1/2 function. They have demonstrated effectiveness against tumors resistant to chemotherapy, including colon, ovarian, breast, and prostate cancer, and are significantly active against hormone-refractory prostate and breast cancer, as well as triple-negative breast cancer. These compounds are also effective against tumors bearing BRCA1/2 mutations and those resistant to conventional PARP inhibitors, as well as tumors bearing KRAS, PIK3CA, MEK, and BRAF mutations.
The second drug, new 1,2,4-triazolo[3,4-b][1,3,4]thiadiazole derivatives (TADs), has demonstrated high cytostatic and cytotoxic activity against human cancer cell lines in vitro and high antitumor effects against human tumor xenografts in vivo. TADs have shown effectiveness against cancer cells resistant to chemotherapeutics, including platinum complexes, doxorubicin, irinotecan, and paclitaxel, and exhibit high activity against colon and pancreatic cancer cells with K-RAS and/or TP53 mutations. They also induce strong inhibition of phosphorylation and activity of Topoisomerase IIa and the PI3K-AKT-mTOR signal transduction cellular pathway. TADs are highly effective against cancer tumors with a defective mismatch repair system (dMMR) and high microsatellite instability (MSI-H), and they trigger the expression of PD-L1 on cancer cells.
